Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Creates Division To Support First Amendment Policy Development, Oversee Advertising Research

Executive Summary

Multiple unfavorable court decisions have forced the agency to adjust its advertising enforcement strategies.

You may also be interested in...



FDA Authorized COVID Drugs Get New Advertising Abilities, Likely Necessitated By First Amendment

Pfizer and Merck indicate they may take advantage of new FDA decision that will give companies more flexibility to tout clinical trial results of COVID-19 therapeutics granted emergency use authorization.

Pfizer’s Paxlovid And The Murky World Of Rx Drug Communication

Pfizer social media announcement that it’s seeking full approval for the oral COVID antiviral raise questions about where the line is on promotion versus other communications, FDA’s ability to regulate pharma on social media, and the unique considerations of promotion under EUAs.

Pfizer’s Paxlovid And The Murky World Of Rx Drug Communication

Pfizer social media announcement that it’s seeking full approval for the oral COVID antiviral raise questions about where the line is on promotion versus other communications, FDA’s ability to regulate pharma on social media, and the unique considerations of promotion under EUAs.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145460

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel